MA39877A - Formes solides d'un composé pharmaceutiquement actif - Google Patents

Formes solides d'un composé pharmaceutiquement actif

Info

Publication number
MA39877A
MA39877A MA039877A MA39877A MA39877A MA 39877 A MA39877 A MA 39877A MA 039877 A MA039877 A MA 039877A MA 39877 A MA39877 A MA 39877A MA 39877 A MA39877 A MA 39877A
Authority
MA
Morocco
Prior art keywords
solid forms
active compound
pharmaceutically active
compound
compositions
Prior art date
Application number
MA039877A
Other languages
English (en)
Inventor
Rudolf Benz
Duk Soon Choi
Ralph Diodone
Zhongjiang Jia
Bharat Patel
Urs Schwitter
Ningxin Yan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA39877A publication Critical patent/MA39877A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des formes solides d'un composé (1) (1), des procédés pour les fabriquer, ainsi que des compositions comprenant ces formes solides.
MA039877A 2014-04-15 2015-04-13 Formes solides d'un composé pharmaceutiquement actif MA39877A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461979649P 2014-04-15 2014-04-15

Publications (1)

Publication Number Publication Date
MA39877A true MA39877A (fr) 2017-02-22

Family

ID=52815005

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039877A MA39877A (fr) 2014-04-15 2015-04-13 Formes solides d'un composé pharmaceutiquement actif

Country Status (18)

Country Link
US (1) US10227298B2 (fr)
EP (2) EP3459933B1 (fr)
JP (2) JP6621761B2 (fr)
KR (1) KR20160138307A (fr)
CN (1) CN106458886A (fr)
AR (1) AR100095A1 (fr)
AU (1) AU2015249018A1 (fr)
BR (1) BR112016023767A2 (fr)
CA (1) CA2943571A1 (fr)
ES (1) ES2928706T3 (fr)
IL (1) IL247974A0 (fr)
MA (1) MA39877A (fr)
MX (1) MX2016013439A (fr)
PL (1) PL3459933T3 (fr)
RU (1) RU2016144187A (fr)
SG (1) SG11201608559QA (fr)
WO (1) WO2015158648A1 (fr)
ZA (1) ZA201606653B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
WO2019213106A1 (fr) 2018-04-30 2019-11-07 Teva Pharmaceuticals International Gmbh Formes à l'état solide d'idasanutline
WO2022183006A1 (fr) 2021-02-25 2022-09-01 Mayo Foundation For Medical Education And Research Composés pour la dégradation de protéine programmable et procédés d'utilisation pour le traitement d'une maladie
WO2023056069A1 (fr) 2021-09-30 2023-04-06 Angiex, Inc. Conjugués agent de dégradation-anticorps et leurs procédés d'utilisation
WO2024240858A1 (fr) 2023-05-23 2024-11-28 Valerio Therapeutics Molécules protac dirigées contre un système de réparation de dommages à l'adn et leurs utilisations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
US8993614B2 (en) * 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
US20130245089A1 (en) 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
CN107540594A (zh) * 2012-05-30 2018-01-05 霍夫曼-拉罗奇有限公司 取代的吡咯烷‑2‑甲酰胺
NZ708272A (en) * 2013-01-22 2020-07-31 Hoffmann La Roche Pharmaceutical composition with improved bioavailability
RU2015133939A (ru) 2013-02-21 2017-03-27 Ф. Хоффманн-Ля Рош Аг Асимметрический синтез замещенного пирролидин-2-карбоксамида

Also Published As

Publication number Publication date
RU2016144187A3 (fr) 2018-11-13
ES2928706T3 (es) 2022-11-22
JP6887980B2 (ja) 2021-06-16
WO2015158648A1 (fr) 2015-10-22
AR100095A1 (es) 2016-09-07
SG11201608559QA (en) 2016-11-29
EP3131878A1 (fr) 2017-02-22
US10227298B2 (en) 2019-03-12
US20170037005A1 (en) 2017-02-09
JP2017511362A (ja) 2017-04-20
JP6621761B2 (ja) 2019-12-18
PL3459933T3 (pl) 2023-01-23
AU2015249018A1 (en) 2016-10-06
KR20160138307A (ko) 2016-12-02
CA2943571A1 (fr) 2015-10-22
EP3459933A3 (fr) 2019-05-29
JP2019055960A (ja) 2019-04-11
EP3459933A2 (fr) 2019-03-27
CN106458886A (zh) 2017-02-22
ZA201606653B (en) 2018-05-30
EP3459933B1 (fr) 2022-08-24
IL247974A0 (en) 2016-11-30
RU2016144187A (ru) 2018-05-16
MX2016013439A (es) 2016-11-17
BR112016023767A2 (pt) 2017-08-15

Similar Documents

Publication Publication Date Title
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
DK3577110T3 (da) 8-oxetan-3-yl-3,8-diazabicyclo[3.2.1]octan-3-yl-substituerede forbindelser som hiv-inhibitorer
PH12019550235A1 (en) Kinase inhibitors and uses thereof
MX2021010418A (es) Composiciones que comprenden una caseína y métodos para producir las mismas.
UY36275A (es) Compuestos aminopirimidinilo
MY192824A (en) Compound targeting il-23a and tnf-alpha and uses thereof
TN2015000519A1 (en) Small molecule inhibitors of fibrosis
PH12015502546B1 (en) 3-(4-isobutyl-2-methylphenyl) propanal as perfume ingredient
UA120058C2 (uk) Пестицидні композиції
IL284800A (en) Methods, uses and compositions
WO2015191945A3 (fr) Formes solides de sofosbuvir
PH12016501252A1 (en) Novel tetrahydropyridopyrimidine compound or salt thereof
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
MX2016010973A (es) Compuestos de aminocarbonilcarbamato.
IN2014MU00455A (fr)
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
PH12018500903A1 (en) Pyranodipyridine compound
MX2016013439A (es) Formas solidas de un compuesto farmaceuticamente activo.
WO2015104720A3 (fr) Compositions parentérales de bendamustine
PH12017502148A1 (en) Pharmaceutical compositions and use thereof
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
WO2016181204A8 (fr) Procédé de fabrication d'un composé à base de mercure, composé à base de mercure, procédés d'utilisation du composé à base de mercure et utilisation du composé à base de mercure
WO2015111004A3 (fr) Méthode améliorée de préparation de chlorophényl-trifluoroéthanone
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
IN2014MU00859A (fr)